It has been over 25 years since I first invented the De Simone Formulation probiotic at my labs in Rome. At that time, the understanding of and appreciation for the importance of the vast microbial community that live within each of us was in its infancy. Today, the clinical significance of the “microbiome” is front and center to a massive array of medical research around the world.
Over these past years, I have had the privilege of working with some of the most preeminent scientific experts in the fields of inflammatory bowel disease, liver disease, irritable bowel syndrome, and oncology. In collaboration with these noted researchers, I am pleased to say that we have produced nearly 60 human clinical trials with the product, making it one of the most widely studied probiotics available. A key result of this research has been the inclusion of my formulation in numerous international consensus treatment guidelines.
As a medical doctor, my commitment is to patients in need and, as a result, it gives me great pleasure to see my product helping so many people manage their chronic conditions.
Recently, I made the decision to end my long-term partnership with VSL Pharmaceuticals, Inc., the company for which I collaborated for many years to produce and market the De Simone Formulation under the trademark, “VSL#3®*”, a trademark owned by VSL Pharmaceuticals, Inc.
I am pleased to announce that my formulation is now available from ExeGi Pharma under the trademarks Visbiome™ and Visbiome™ Extra Strength. I decided to work with ExeGi Pharma because of their commitment to product quality and consistency. Physicians and patients can be confident that Visbiome contains the same strains, in the same concentrations and proportions, as the VSL#3® probiotic blend as produced before January 31, 2016.
Professor Claudio De Simone